Both in vivo and in vitro studies indicate that PPARγ ligands, such as Troglitizone, can promote differentiation, inhibit cellular proliferation, induce autophagy, and enhance apoptosis in bladder cancer [26–29]. This evidence concerns the gene PPARG and urinary bladder cancer.